In summary, the patients with locally advanced resectable colon cancer experienced a significant downstaging effect on the tumor without increased perioperative morbidity, although the EGFR antibody therapy, which was added for a proportion of the study population, did not add to the chemotherapy effect [15]. The gene discussed is EGFR; the disease is neoplasm.